At the news
? NEUTRALIMPACT 3/10 SC 13G/A filed Nov 6, 2026 at 11:07 ET
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing an 11.6% passive stake in Vaxcyte as of October 31, 2026, up from 9.6% in the prior filing. The increase reflects continued accumulation by a major institutional holder following positive Phase 3 data for VAX-31 and a recent $1.1B capital raise.
- T. Rowe Price Investment Management disclosed beneficial ownership of 18,136,166 shares of Vaxcyte common stock as of October 31, 2026.
- The stake represents 11.6% of shares outstanding, up from 9.6% in the prior filing.
- The filing is a passive investor update under Rule 13d-1(b); the investor certifies shares were not acquired to influence control.
- T. Rowe Price Capital Appreciation Fund holds 7,430,887 shares (5.2% of class) within the total.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access